Limitations in Immunotherapy with CD3 Antibodies: Comment on the Article by Drs. Chatenoud and Bach

SBDR - SOCIETY FOR BIOMEDICAL DIABETES RESEARCH
Limitations in Immunotherapy with CD3 Antibodies: Comment on the Article by Drs. Chatenoud and Bach

Our Mission

Membership

Diabetes Open Directory

The Review of Diabetic Studies

For Authors

Research

Support the SBDR

SBDR>The Review of Diabetic Studies>Archive>2>4-Winter>Commentary> Limitations in Immunotherapy with CD3 Antibodies

Limitations in Immunotherapy with CD3 Antibodies

Commentary

Rev Diabet Stud, 2005, 2(4):187-189

DOI 10.1900/RDS.2005.2.187

Limitations in Immunotherapy with CD3 Antibodies: Comment on the Article by Drs. Chatenoud and Bach

Damien Bresson, Matthias von Herrath

La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology 3, 10355 Science Center Drive, San Diego, California 92121, USA.
Address correspondence to: Matthias von Herrath, e-mail: matthias@liai.org

Abstract

n/a

Fulltext: HTML , PDF (174KB)

This article has been cited by other articles:

"Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?

Sia C, Weinem M

Rev Diabet Stud 2006. 3(4):156-160

Internal Link

Limitations in Immunotherapy with CD3 Antibodies: Comment on the Article by Drs. Chatenoud and Bach (174KB)